Display options
Cite
Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question?. Am J Transl Res. 2013;5(6):563-81
Irollo, E., & Pirozzi, G. (2013). CD133: to be or not to be, is this the real question?. American journal of translational research, 5(6), 563-81.
Irollo, Elena, and Pirozzi, Giuseppe. "CD133: to be or not to be, is this the real question?." American journal of translational research vol. 5,6 (2013): 563-81.
Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question?. Am J Transl Res. 2013 Sep 25;5(6):563-81. PMID: 24093054; PMCID: PMC3786264.
Copy Download .nbib Format: NLM
Share it on

Am J Transl Res. 2013 Sep 25;5(6):563-81.

CD133: to be or not to be, is this the real question?.

American journal of translational research

Elena Irollo, Giuseppe Pirozzi

Affiliations

  1. Department of Experimental Oncology, Istituto Nazionale Tumori Fondazione G. Pascale Naples, Italy.

PMID: 24093054 PMCID: PMC3786264

Abstract

CD133 (promini-1) is a member of the transmembrane glycoprotein family, was initially described as a specific marker to select human hematopoietic progenitor cells. Then, it was recognised as important marker to identify and isolate the specific cell subpopulation termed "cancer stem cells". Many studies showed that CD133(+) cells have stemness properties such as self-renewal, differentiation ability, high proliferation and they are able also to form tumours in xenografts. Moreover it has been demonstrated that CD133(+) cells more resistant to radiation and standard chemotherapy than CD133(-) cells. Although this, others investigations demonstrated that also CD133(-) cells can show the same characteristics of those positive for CD133(+). Hence, some inconsistencies among published data on CD133 function can be ascribed to different causes questioning the main role as specific marker of cancer stem cells. In fact, many authors indicate that CD133 is expressed both in differentiated and undifferentiated cells, and CD133(-) cancer cells can also initiate tumours. Indeed, it is still a matter of debate whether CD133(+) cells truly represent the ultimate tumourigenic population. However, the belief that CD133 may act as a universal marker of CSCs has been met with a high degree of controversy in the research community. In this review there is an attempt to highlight: i) the role and function of CD133, with an overview on the current stage of knowledge about this molecule, ii) the difficulty often encountered in its identification iii) the utility of CD133 expression as a prognostic marker.

Keywords: Prominin-1 (CD133); cancer stem cells; circulating tumor cells; epigenetic regulation; epithelial-mesenchymal transition; glycosylation

References

  1. J Clin Oncol. 2009 Nov 1;27(31):5153-9 - PubMed
  2. Blood. 1997 Dec 15;90(12):5013-21 - PubMed
  3. Cancer Res. 2002 Dec 15;62(24):7213-8 - PubMed
  4. Traffic. 2001 Feb;2(2):82-91 - PubMed
  5. Eur J Cancer. 2007 Mar;43(5):935-46 - PubMed
  6. Glycoconj J. 2004;20(3):189-98 - PubMed
  7. Cell Res. 2008 Oct;18(10):1037-46 - PubMed
  8. Br J Cancer. 2008 Oct 21;99(8):1285-9 - PubMed
  9. J Biol Chem. 2003 Mar 7;278(10):8586-96 - PubMed
  10. Blood. 2004 Mar 15;103(6):2055-61 - PubMed
  11. N Engl J Med. 2006 Sep 21;355(12):1253-61 - PubMed
  12. J Neurooncol. 2013 Dec;115(3):333-41 - PubMed
  13. Transl Oncol. 2012 Jun;5(3):141-54 - PubMed
  14. Hum Pathol. 2010 Nov;41(11):1516-29 - PubMed
  15. Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 - PubMed
  16. PLoS One. 2011;6(6):e21548 - PubMed
  17. Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30 - PubMed
  18. Cancer Cell. 2006 May;9(5):391-403 - PubMed
  19. Heredity (Edinb). 2010 Jul;105(1):4-13 - PubMed
  20. J Biol Chem. 2000 Feb 25;275(8):5512-20 - PubMed
  21. J Biol Chem. 2011 Nov 25;286(47):41046-56 - PubMed
  22. Am J Physiol Renal Physiol. 2008 Sep;295(3):F680-7 - PubMed
  23. Cell Tissue Res. 2005 Jan;319(1):15-26 - PubMed
  24. Blood. 2000 Feb 1;95(3):952-8 - PubMed
  25. J Invest Dermatol. 2007 May;127(5):1052-60 - PubMed
  26. Cancer Sci. 2009 Jun;100(6):1040-6 - PubMed
  27. Cancer Res. 2011 Jun 1;71(11):3991-4001 - PubMed
  28. MLO Med Lab Obs. 2010 Apr;42(4):32, 34-6 - PubMed
  29. J Am Soc Nephrol. 2006 Sep;17(9):2443-56 - PubMed
  30. Cancer Res. 2007 May 15;67(10):4827-33 - PubMed
  31. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 - PubMed
  32. Cancer Res. 2003 Sep 15;63(18):5821-8 - PubMed
  33. Mol Cancer. 2010 Feb 19;9:39 - PubMed
  34. Stem Cells. 2007 Jan;25(1):2-9 - PubMed
  35. PLoS One. 2008;3(10):e3469 - PubMed
  36. Int J Cancer. 2011 Jul 15;129(2):417-23 - PubMed
  37. Nature. 2007 Jan 4;445(7123):111-5 - PubMed
  38. Cell. 2006 Apr 21;125(2):301-13 - PubMed
  39. J Breast Cancer. 2012 Mar;15(1):15-23 - PubMed
  40. Nat Genet. 2007 Feb;39(2):237-42 - PubMed
  41. Oncol Rep. 2010 Aug;24(2):537-46 - PubMed
  42. Vet J. 2008 Jan;175(1):69-75 - PubMed
  43. Nature. 2009 Jan 29;457(7229):603-7 - PubMed
  44. Oncol Rep. 2013 May;29(5):1763-8 - PubMed
  45. J Cell Physiol. 2012 Jun;227(6):2686-93 - PubMed
  46. Biochem Biophys Res Commun. 2007 Jan 12;352(2):410-7 - PubMed
  47. Curr Opin Genet Dev. 2010 Feb;20(1):96-9 - PubMed
  48. Nature. 2004 Nov 18;432(7015):396-401 - PubMed
  49. Cancer Res. 2010 Jan 15;70(2):719-29 - PubMed
  50. Annu Rev Genet. 1996;30:441-64 - PubMed
  51. Int J Clin Exp Pathol. 2010 Dec 04;4(1):32-42 - PubMed
  52. Biochem Biophys Res Commun. 2001 Jul 27;285(4):939-44 - PubMed
  53. Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 - PubMed
  54. J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 - PubMed
  55. Anticancer Res. 2010 Jun;30(6):2453-7 - PubMed
  56. Stem Cells. 2008 Apr;26(4):920-6 - PubMed
  57. J Thorac Dis. 2012 Oct;4(5):438-9 - PubMed
  58. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 - PubMed
  59. Cell Stem Cell. 2007 Nov;1(5):555-67 - PubMed
  60. Eur J Cancer. 2010 Feb;46(3):642-9 - PubMed
  61. J Transl Med. 2009 Jul 07;7:56 - PubMed
  62. Cell Death Dis. 2013 May 02;4:e620 - PubMed
  63. Bioessays. 2007 Sep;29(9):842-5 - PubMed
  64. Cancer Res. 2005 Dec 1;65(23):10946-51 - PubMed
  65. Cell Death Differ. 2008 Mar;15(3):504-14 - PubMed
  66. J Cell Physiol. 2010 Jul;224(1):234-41 - PubMed
  67. J Pathol. 2013 Feb;229(3):355-78 - PubMed
  68. Circulation. 2005 Mar 8;111(9):1175-83 - PubMed
  69. Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 - PubMed
  70. Blood. 2003 Jan 1;101(1):168-72 - PubMed
  71. Cell Prolif. 2012 Dec;45(6):527-37 - PubMed
  72. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 - PubMed
  73. Cancer Lett. 2009 Jun 18;278(2):164-173 - PubMed
  74. Cancer Res. 2009 Feb 15;69(4):1302-13 - PubMed
  75. FASEB J. 2011 Jun;25(6):2022-30 - PubMed
  76. Exp Hematol. 2007 Aug;35(8):1279-92 - PubMed
  77. World J Gastroenterol. 2009 May 14;15(18):2258-64 - PubMed
  78. Annu Rev Pathol. 2009;4:229-49 - PubMed
  79. Blood. 1997 Dec 15;90(12):5002-12 - PubMed
  80. Cell Stem Cell. 2007 Sep 13;1(3):313-23 - PubMed
  81. Expert Opin Biol Ther. 2010 Nov;10(11):1521-8 - PubMed
  82. Gan To Kagaku Ryoho. 2012 Nov;39(12):1763-5 - PubMed
  83. BMC Cancer. 2008 Feb 08;8:48 - PubMed
  84. Cell. 2009 Nov 25;139(5):871-90 - PubMed
  85. Exp Cell Res. 2005 Jun 10;306(2):330-5 - PubMed
  86. J Biosci. 2010 Dec;35(4):665-73 - PubMed
  87. Eur J Cardiothorac Surg. 2009 Sep;36(3):446-53 - PubMed
  88. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):175-80 - PubMed
  89. Nat Neurosci. 2005 Jun;8(6):723-9 - PubMed
  90. J Pathol. 2009 Dec;219(4):427-34 - PubMed
  91. Nature. 2001 Nov 1;414(6859):105-11 - PubMed
  92. Ann Surg Oncol. 2011 Oct;18(10):2937-45 - PubMed
  93. Cancer Lett. 2008 Sep 8;268(1):1-9 - PubMed
  94. Cancer Sci. 2008 Aug;99(8):1578-83 - PubMed
  95. Int J Cancer. 2008 Feb 15;122(4):761-8 - PubMed
  96. Oncogene. 2009 Jan 15;28(2):209-18 - PubMed
  97. Pancreas. 2008 Jan;36(1):e1-6 - PubMed
  98. Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jul;16(7):662-7 - PubMed
  99. Nature. 2007 Jan 4;445(7123):106-10 - PubMed
  100. PLoS One. 2013;8(3):e59154 - PubMed
  101. Cell Mol Life Sci. 2000 Dec;57(13-14):1964-9 - PubMed
  102. Int J Cancer. 2013 Nov 15;133(10):2398-407 - PubMed
  103. Cancer Res. 2008 Oct 1;68(19):8094-103 - PubMed
  104. Mol Cancer Ther. 2012 Nov;11(11):2526-34 - PubMed
  105. J Clin Invest. 2008 Jun;118(6):2111-20 - PubMed
  106. Lab Invest. 2012 Mar;92(3):420-36 - PubMed
  107. Leukemia. 2000 Apr;14(4):770-2 - PubMed
  108. Int J Cancer. 2007 Apr 1;120(7):1444-50 - PubMed
  109. Gastroenterology. 2007 Feb;132(2):720-32 - PubMed
  110. J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34 - PubMed
  111. J Mol Med (Berl). 2008 Sep;86(9):1025-32 - PubMed
  112. J Clin Invest. 2004 Jul;114(2):182-95 - PubMed
  113. Neoplasia. 2005 Nov;7(11):967-76 - PubMed
  114. J Pathol. 2008 Jan;214(1):3-9 - PubMed
  115. Oncogene. 2009 Nov 12;28(45):3949-59 - PubMed
  116. Int J Oncol. 2012 Jan;40(1):71-9 - PubMed
  117. Cell Stem Cell. 2007 Oct 11;1(4):389-402 - PubMed
  118. Cancer Invest. 2012 Jun;30(5):390-7 - PubMed
  119. Mol Interv. 2006 Jun;6(3):140-8 - PubMed
  120. Nat Cell Biol. 2000 Sep;2(9):582-92 - PubMed
  121. Int J Biol Sci. 2008 May 04;4(3):133-42 - PubMed
  122. Am J Clin Pathol. 2009 Aug;132(2):237-45 - PubMed

Publication Types